At CES 2026, Withings introduced the Body Scan 2, a connected scale positioned as a more comprehensive at-home health monitoring device rather than a simple weight tracker. The company says the new model can identify certain cardiovascular and metabolic risk indicators, including signals associated with hypertension, without relying on traditional medical accessories such as blood pressure cuffs.
Body Scan 2 builds on the original Body Scan design by combining a conventional floor scale with a retractable handle. During a roughly 90-second session, users stand on the platform and hold the handle to allow electrical and biometric sensors to collect data across the body. According to Withings, the system tracks more than 60 biomarkers, spanning body composition, cardiovascular metrics, and metabolic indicators. Some of these measurements expand on features seen in earlier Withings products, while others are new to the lineup.
One of the more notable additions is a hypertension risk notification. Instead of measuring blood pressure directly, Body Scan 2 uses impedance data and an AI-based model to estimate arterial hypertension risk. The intent is not to replace clinical diagnosis, but to flag patterns that may warrant further attention. Withings is positioning this as a preventive tool, aimed at identifying elevated risk earlier than many people would otherwise notice.
Another new feature focuses on glycemic health. The scale can now detect signs of glycemic dysregulation, which may indicate an increased risk of conditions such as prediabetes. While this does not provide a blood glucose reading, it is meant to offer contextual insight into metabolic trends over time. Body Scan 2 also introduces Impedance Cardiography, a technique typically used in clinical settings to assess how effectively the heart pumps blood. Applied here, it is intended to highlight potential inefficiencies or abnormalities in cardiac function.
Withings states that many of these measurements are clinically validated and designed to encourage practical lifestyle changes, particularly around activity, diet, sleep, and stress. The company frames the product as a response to long-term, often unnoticed health shifts linked to modern habits rather than as a diagnostic medical device.
To make the data more approachable, Body Scan 2 introduces a Health Trajectory score, which summarizes how current trends may influence long-term health outcomes. Like other Withings scales, it integrates with third-party platforms, including Fitbit, via Android Health Connect. The device syncs over Wi-Fi or Bluetooth and is rated for up to 15 months of battery life.
Body Scan 2 is scheduled to launch in the second quarter of 2026. In the US, pricing is set at $599, reflecting a $100 increase over the previous generation. That price positions it firmly at the premium end of the smart scale market, likely limiting its appeal to users who are already invested in detailed health tracking rather than casual fitness monitoring.
